3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Isoprenaline.
Acebutolol
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Acebutolol.
Acemetacin
The therapeutic efficacy of Acemetacin can be decreased when used in combination with Isoprenaline.
Advertisement
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Isoprenaline.
Alprenolol
Alprenolol may decrease the bronchodilatory activities of Isoprenaline.
AMBROXOL ACEFYLLINATE
The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Isoprenaline.
Advertisement
Ambroxol-Theophylline-7-Acetate
The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Isoprenaline.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Isoprenaline.
Aminophylline
The serum concentration of Aminophylline can be decreased when it is combined with Isoprenaline.
Advertisement
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Isoprenaline.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Isoprenaline.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Isoprenaline.
Atenolol
Atenolol may decrease the bronchodilatory activities of Isoprenaline.
Atomoxetine
Atomoxetine may increase the hypertensive activities of Isoprenaline.
Atosiban
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Atosiban.
Azosemide
Isoprenaline may increase the hypokalemic activities of Azosemide.
Bendroflumethiazide
Isoprenaline may increase the hypokalemic activities of Bendroflumethiazide.
Benzphetamine
The risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoprenaline.
Benzylpenicilloyl polylysine
Isoprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betahistine.
Betaxolol
Betaxolol may decrease the bronchodilatory activities of Isoprenaline.
Bisoprolol
Bisoprolol may decrease the bronchodilatory activities of Isoprenaline.
Bopindolol
Bopindolol may decrease the bronchodilatory activities of Isoprenaline.
Bromocriptine
Bromocriptine may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Bumetanide
Isoprenaline may increase the hypokalemic activities of Bumetanide.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Isoprenaline.
Bupranolol
Bupranolol may decrease the bronchodilatory activities of Isoprenaline.
Cabergoline
Cabergoline may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Calcium Carbimide
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Isoprenaline.
Carteolol
Carteolol may decrease the bronchodilatory activities of Isoprenaline.
Carvedilol
Carvedilol may decrease the vasoconstricting activities of Isoprenaline.
Celiprolol
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Celiprolol.
Chlorothiazide
Isoprenaline may increase the hypokalemic activities of Chlorothiazide.
Chlorthalidone
Isoprenaline may increase the hypokalemic activities of Chlorthalidone.
Clenbuterol
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Clenbuterol.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Isoprenaline.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoprenaline.
Cyclopenthiazide
Isoprenaline may increase the hypokalemic activities of Cyclopenthiazide.
Desflurane
Desflurane may increase the arrhythmogenic activities of Isoprenaline.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Isoprenaline.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Isoprenaline.
Dihydroergotamine
Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Dobutamine
The risk or severity of adverse effects can be increased when Dobutamine is combined with Isoprenaline.
Dopamine
The risk or severity of adverse effects can be increased when Dopamine is combined with Isoprenaline.
Dothiepin
The risk or severity of adverse effects can be increased when Dosulepin is combined with Isoprenaline.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Isoprenaline.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Isoprenaline.
Duloxetine
Duloxetine may increase the tachycardic activities of Isoprenaline.
Dyphylline
The serum concentration of Dyphylline can be decreased when it is combined with Isoprenaline.
Enflurane
Enflurane may increase the arrhythmogenic activities of Isoprenaline.
Ephedrine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Ephedrine.
Epinephrine
The risk or severity of adverse effects can be increased when Epinephrine is combined with Isoprenaline.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Ergonovine
Ergonovine may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Ergotamine
Ergotamine may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Esmolol
Esmolol may decrease the bronchodilatory activities of Isoprenaline.
Ethacrynate
Isoprenaline may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Isoprenaline may increase the hypokalemic activities of Etacrynic acid.
Etilefrine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Etilefrine.
Fenoterol
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Fenoterol.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.
Furosemide
Isoprenaline may increase the hypokalemic activities of Furosemide.
Halothane
Halothane may increase the arrhythmogenic activities of Isoprenaline.
Hydrochlorothiazide
Isoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Isoprenaline may increase the hypokalemic activities of Hydroflumethiazide.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Isoprenaline.
Indapamide
Isoprenaline may increase the hypokalemic activities of Indapamide.
Indoramin
Indoramin may decrease the vasoconstricting activities of Isoprenaline.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Isoprenaline.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoprenaline.
Isoflurane
Isoflurane may increase the arrhythmogenic activities of Isoprenaline.
Isoxsuprine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Isoxsuprine.
Labetalol
The risk or severity of adverse effects can be increased when Labetalol is combined with Isoprenaline.
Lacidipine
Isoprenaline may increase the hypotensive activities of Lacidipine.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Isoprenaline.
Linezolid
Linezolid may increase the hypertensive activities of Isoprenaline.
Mephentermine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephentermine.
Metaproterenol
The risk or severity of adverse effects can be increased when Orciprenaline is combined with Isoprenaline.
Metaraminol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Isoprenaline.
Methamphetamine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Methamphetamine.
Methoxamine
The risk or severity of adverse effects can be increased when Methoxamine is combined with Isoprenaline.
Methoxyflurane
Methoxyflurane may increase the arrhythmogenic activities of Isoprenaline.
Methyclothiazide
Isoprenaline may increase the hypokalemic activities of Methyclothiazide.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Isoprenaline.
Methylergonovine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Metolazone
Isoprenaline may increase the hypokalemic activities of Metolazone.
Metoprolol
Metoprolol may decrease the bronchodilatory activities of Isoprenaline.
Midodrine
The risk or severity of adverse effects can be increased when Midodrine is combined with Isoprenaline.
Milnacipran
Milnacipran may increase the tachycardic activities of Isoprenaline.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Isoprenaline.
Mirtazapine
The risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoprenaline.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Isoprenaline.
Nabilone
Nabilone may increase the tachycardic activities of Isoprenaline.
Nebivolol
Nebivolol may decrease the bronchodilatory activities of Isoprenaline.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Isoprenaline.
Nitrous Oxide
Nitrous oxide may increase the arrhythmogenic activities of Isoprenaline.
Norepinephrine
The risk or severity of adverse effects can be increased when Norepinephrine is combined with Isoprenaline.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Isoprenaline.
Nylidrin
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Nylidrin.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Isoprenaline.
Oxprenolol
Oxprenolol may decrease the bronchodilatory activities of Isoprenaline.
Oxymetazoline
The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoprenaline.
p-Hydroxyamphetamine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Hydroxyamphetamine.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Isoprenaline.
Phenmetrazine
The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoprenaline.
Phentermine
The risk or severity of adverse effects can be increased when Phentermine is combined with Isoprenaline.
PHENTERMINE RESIN
The risk or severity of adverse effects can be increased when Phentermine is combined with Isoprenaline.
Phenylephrine
The risk or severity of adverse effects can be increased when Phenylephrine is combined with Isoprenaline.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Isoprenaline.
Piretanide
Isoprenaline may increase the hypokalemic activities of Piretanide.
Polythiazide
Isoprenaline may increase the hypokalemic activities of Polythiazide.
Prazosin
Prazosin may decrease the vasoconstricting activities of Isoprenaline.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoprenaline.
Procaterol
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Procaterol.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline.
Pseudoephedrine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Pseudoephedrine.
Quinethazone
Isoprenaline may increase the hypokalemic activities of Quinethazone.
Racepinephrine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Racepinephrine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Isoprenaline.
Ritodrine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoprenaline.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Isoprenaline.
Sevoflurane
Sevoflurane may increase the arrhythmogenic activities of Isoprenaline.
Silodosin
Silodosin may decrease the vasoconstricting activities of Isoprenaline.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Isoprenaline.
Synephrine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Synephrine.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Isoprenaline.
Tedizolid
Tedizolid Phosphate may increase the hypertensive activities of Isoprenaline.
Tedizolid Phosphate
Tedizolid Phosphate may increase the hypertensive activities of Isoprenaline.
Terazosin
Terazosin may decrease the vasoconstricting activities of Isoprenaline.
Terbutaline
The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.
Tetrahydrocannabinol
Dronabinol may increase the tachycardic activities of Isoprenaline.
Tetrahydrozoline
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tetryzoline.
Theophylline
The serum concentration of Theophylline can be decreased when it is combined with Isoprenaline.
Theophylline anhydrous
The serum concentration of Theophylline can be decreased when it is combined with Isoprenaline.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Isoprenaline.
Timolol
Timolol may decrease the bronchodilatory activities of Isoprenaline.
Timolol Anhydrous
Timolol may decrease the bronchodilatory activities of Isoprenaline.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Isoprenaline.
Torsemide
Isoprenaline may increase the hypokalemic activities of Torasemide.
Tramazoline
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tramazoline.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.
Trichlormethiazide
Isoprenaline may increase the hypokalemic activities of Trichlormethiazide.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Isoprenaline.
Tyramine
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tyramine.
Urapidil
Urapidil may decrease the vasoconstricting activities of Isoprenaline.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Isoprenaline.
